Thursday, September 23, 2021

Onconova Therapeutics (ONTX)
Rigosertib Phase 1/2a Data Presentation Confirms Optimism

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 1/2a Data Presented On Sept 22, 2021. Onconova presented data at the 3rd Annual RAS Targeted Drug Development Summit from its Phase 1/2a trial in non-small cell lung cancer (NSCLC).  Afterward, the company held a conference call in which the Principle Investigator presented the preclinical data, Phase 1/2a trial data, and answered questions.


Lead Trial Investigator Presented Data.  The preclinical data discussion reviewed rigosertib’s mechanism of action and pathways.  This included a discussion of how the KRAS mutations lead to loss of control over the cell proliferation process, rigosertib animal models, and data in combination with checkpoint inhibitors …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.